Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MYGN - MYRIAD GENETICS INC


IEX Last Trade
13.74
-14.730   -107.205%

Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%

$28.47
-14.73
-51.74%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 9%
Liquidity 27%
Performance 1%
Company vs Stock growth
vs
Performance
5 Days
2.84%
1 Month
-12.54%
3 Months
-47.34%
6 Months
-44.28%
1 Year
-32.32%
2 Year
-10.61%
Key data
Stock price
$13.74
P/E Ratio 
-16.58
DAY RANGE
$13.42 - $28.47
EPS 
-$1.78
52 WEEK RANGE
$13.39 - $29.30
52 WEEK CHANGE
-$30.54
MARKET CAP 
2.573 B
YIELD 
N/A
SHARES OUTSTANDING 
90.820 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,290,325
AVERAGE 30 VOLUME 
$1,096,290
Company detail
CEO: Paul J. Diaz
Region: US
Website: myriad.com
Employees: 2,600
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.

Recent news